Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.

Molecular carcinogenesis - 1 Jan 2024

Lahera Antonio, Vela-Martín Laura, Fernández-Navarro Pablo, Llamas Pilar, López-Lorenzo José L, Cornago Javier, Santos Javier, Fernández-Piqueras José, Villa-Morales María

Abstract excerpt

T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell progenitors at various differentiation stages. Given that patients who relapse have a dismal prognosis, there is an urgent need to identify the molecular alterations that are present in such patients and promote leukemogenesis to implement personalized therapies with higher efficacy and fewer adverse effects. In the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 3
Share to Janus Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyrazoles

Share to Pyrimidines

Share to Recurrence

Share to STAT Transcription Factors

Source

Identifiers

PMID: 37712558
DOI: 10.1002/mc.23632

Genes

IL2RG
JAK1
JAK3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.PMID 37712558Read ↗

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsSemantic proximity Read ↗

Research progress on the mechanisms of CSF3R mutations in leukemogenesis and treatment strategiesSemantic proximity Read ↗

Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.Semantic proximity Read ↗

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.Semantic proximity Read ↗

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemiaSemantic proximity Read ↗

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Semantic proximity Read ↗

Roles of STAT3 in leukemia (Review)Semantic proximity Read ↗

FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.Semantic proximity Read ↗

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.Semantic proximity Read ↗

Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.Semantic proximity Read ↗

Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.